Here’s what you should know:
1. People who completed either of the first T3MPO phase III studies were eligible for the safety extension study, T3MPO-3.
2. Tenapanor was well-tolerated among the 240 patients that were studied.
3. Of the 240 patients, 9.2 percent experienced diarrhea, with only 1.7 percent of patients discontinuing the treatment because of diarrhea.
4. Throughout all the clinical trials, overall discontinuation rate was only 2.1 percent.
5. Ardelyx plans to submit positive results from the first two T3MPO trials, along with extensive safety data, to the FDA in the second half of 2018 for approval.
More articles on gastroenterology:
GI leader to know: Dr. Elisa Faybush of Arizona Digestive Health
Allergan, Karl Storz Endoscopy & more — 4 GI company key notes
Low-dose polyethylene glycol-based bowel preparation solution acceptable — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
